Zealand Pharma A/S (OTCMKTS:ZLDPF) Now Covered by JPMorgan Chase & Co.

Research analysts at JPMorgan Chase & Co. began coverage on shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) in a note issued to investors on Friday, Marketbeat Ratings reports. The brokerage set an “overweight” rating on the stock.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF opened at $119.04 on Friday. The stock’s 50 day moving average is $122.93 and its two-hundred day moving average is $115.43. Zealand Pharma A/S has a twelve month low of $40.40 and a twelve month high of $141.74. The company has a quick ratio of 35.57, a current ratio of 35.57 and a debt-to-equity ratio of 0.03.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.06). Zealand Pharma A/S had a negative return on equity of 18.17% and a negative net margin of 191.92%. The firm had revenue of $4.93 million during the quarter, compared to analyst estimates of $0.50 million. On average, equities analysts expect that Zealand Pharma A/S will post -2.48 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.